Ruxolitinib and Myelofibrosis: A Treatment Breakthrough

Myelofibrosis (MF) is a clonal hematopoietic disorder characterized by progressive bone marrow fibrosis, cytopenias, massive splenomegaly from extramedullary hematopoiesis, and debilitating constitutional symptoms. The pathophysiology centers on constitutive JAK-STAT activation — most commonly through the JAK2 V617F mutation — that drives myeloid clonal expansion and a cytokine storm responsible for fibrosis and systemic symptoms. Ruxolitinib (Jakafi/Jakavi) was the first therapy proven to reduce spleen size, alleviate symptoms, and extend survival in MF, fundamentally changing how this condition is managed.

The Disease Burden of Myelofibrosis

Myelofibrosis carries substantial morbidity and mortality. Median survival in intermediate-2 and high-risk MF (as classified by the Dynamic International Prognostic Scoring System, DIPSS-plus) is 3–5 years without treatment. The splenomegaly that arises from extramedullary hematopoiesis causes early satiety, abdominal discomfort, and portal hypertension. Constitutional symptoms — profound fatigue, drenching night sweats, bone and joint pain, pruritus, and weight loss — impair quality of life severely. The JAK-driven cytokine excess (elevated IL-6, IL-8, TNF-alpha, IP-10, and many others) is directly responsible for both the constitutional symptoms and the progressive bone marrow fibrosis through stimulation of myofibroblast activity.

Ruxolitinib's Mechanism

Ruxolitinib is a potent, selective inhibitor of JAK1 and JAK2. At therapeutic concentrations, it inhibits JAK2 activity regardless of whether JAK2 V617F, CALR, MPL, or other MPN-driving mutations are present — explaining its efficacy across the mutational spectrum. JAK2 inhibition reduces JAK2-driven myeloid progenitor proliferation. JAK1 inhibition reduces pro-inflammatory cytokine signaling, which correlates directly with symptom improvement and is likely the primary mechanism of constitutional symptom resolution and spleen size reduction (through anti-inflammatory effects in the splenic niche).

Clinical Evidence and Survival Benefit

The COMFORT-I and COMFORT-II trials established ruxolitinib's efficacy (see our overview of the full JAK inhibitor landscape for details). Extended 5-year survival data from COMFORT-I demonstrated that patients randomized to ruxolitinib had significantly better overall survival than those initially randomized to placebo, even though most placebo-arm patients eventually crossed over to ruxolitinib. This persistent survival benefit — the most compelling argument for early treatment initiation — is thought to reflect the prolonged anti-inflammatory and anti-fibrotic effects of continuous JAK-STAT suppression.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially curative approach for MF but carries substantial transplant-related mortality. Pre-transplant ruxolitinib therapy can reduce spleen size and disease burden, improving transplant eligibility and outcomes. Emerging therapies — combining ruxolitinib with BET bromodomain inhibitors, BCL2 inhibitors, telomerase inhibitors, or immunomodulatory agents — are being evaluated to address the unmet need for disease modification (not just symptom control) in MF. For the biology underlying JAK2 mutations and signaling, see our article on JAK1 vs JAK2 vs JAK3.

For more information, visit our homepage or our resources section.